APRE
APREA THERAPEUT (APRE)
NASDAQ
$0.83+$0.04 (+4.71%)
Price as of Jun 23, 2026 7:44 PM EDT
  • $9.8M
    Market Cap
  • -50.40%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-7.0M
-24.78%
-9.4M
+22.76%
-7.6M
-91.75%
-92.4M
+286.77%
Depreciation and Amortization Expense
21,715
-2.70%
22,318
+216.48%
7,052
+60.16%
4,403
-65.68%
Total Operating Expenses
13.5M
-14.55%
15.8M
-1.45%
16.1M
-85.84%
113.4M
+202.81%
Operating Profit
-13.2M
-7.58%
-14.3M
-7.45%
-15.5M
-86.27%
-112.7M
+203.45%
Interest Income
77,500
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
77,500
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
634,267
-53.40%
1.4M
+14.83%
1.2M
+62.31%
730,201
+128.87%
Income before Taxes
-13.2M
-7.58%
-14.3M
-7.45%
-15.5M
-86.27%
-112.7M
+203.45%
Income Taxes
0
N/A
0
N/A
0
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-12.6M
-2.77%
-13.0M
-9.30%
-14.3M
-87.32%
-112.7M
+203.45%
Net Income from Continuing Operations Applicable to Common
-12.6M
-2.77%
-13.0M
-9.30%
-14.3M
-87.32%
-112.7M
+203.45%
Basic EPS and Net Income
-1.93
-17.87%
-2.35
-40.51%
-3.95
-94.19%
-67.99
+3,807.47%
Diluted EPS and Net Income
-1.93
-21.22%
-2.45
-37.97%
-3.95
-94.20%
-68.16
+3,817.24%
Basic Weighted Average Shares
6.5M
+18.67%
5.5M
+52.31%
3.6M
+118.32%
1.7M
-92.22%
Diluted Weighted Average Shares
6.5M
+18.67%
5.5M
+52.31%
3.6M
+118.32%
1.7M
-92.22%
Balance Sheet
Cash and Cash Equivalents
14.6M
-36.11%
22.8M
+5.75%
21.6M
-24.94%
28.8M
-45.76%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
14.6M
-36.11%
22.8M
+5.75%
21.6M
-24.94%
28.8M
-45.76%
Total Current Assets
15.6M
-34.00%
23.6M
+4.68%
22.5M
-25.31%
30.2M
-46.71%
Accumulated Depreciation
94,155
+29.98%
72,440
+44.53%
50,122
+16.37%
43,070
-63.19%
Property and Plant and Equipment and Net
59,807
-26.64%
81,522
-7.74%
88,362
+3,707.07%
2,321
-90.28%
Total Long-Term Assets
271,162
-3.73%
281,662
+218.76%
88,362
+200.84%
29,372
0.00%
Total Assets
15.9M
-33.55%
24.0M
+5.87%
22.7M
-24.89%
30.2M
-46.93%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
2.8M
-17.75%
3.4M
-23.36%
4.4M
+37.00%
3.2M
-56.25%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Liabilities
2.8M
-17.75%
3.4M
-23.36%
4.4M
+37.00%
3.2M
-56.25%
Retained Earnings
-333.6M
+3.92%
-321.0M
+4.21%
-308.1M
+4.86%
-293.8M
+62.20%
Total Stockholders Equity
12.4M
-35.56%
19.3M
+13.88%
17.0M
-33.89%
25.6M
-48.20%
Total Shares Outstanding
8.2M
+49.47%
5.5M
+46.68%
3.7M
+40.73%
2.7M
-87.85%
Cash Flow
Cash from Operating Activities
-12.9M
-4.89%
-13.6M
+11.32%
-12.2M
-51.31%
-25.0M
-33.63%
Capital Expenditures
15,478
0.00%
15,478
-83.37%
93,093
+262.10%
25,709
0.00%
Cash from Investing Activities
-15,478
0.00%
-15,478
-83.37%
-93,093
+262.10%
-25,709
0.00%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
4.6M
-68.69%
14.8M
+188.36%
5.1M
+652.59%
682,973
-60.91%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-63.14%
+13.59%
-55.58%
+2.72%
-54.11%
-79.11%
-259.05%
+422.02%
Return on Equity
-79.37%
+11.05%
-71.47%
+6.55%
-67.08%
-77.63%
-299.83%
+412.41%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
5.63
-19.75%
7.01
+36.60%
5.14
-45.49%
9.42
+21.80%
Cash Ratio
5.28
-22.32%
6.80
+37.99%
4.93
-45.21%
8.99
+23.97%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow